• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿尔茨海默病患者血浆肝型脂肪酸结合蛋白与淀粉样β和tau 水平的相关性。

The Correlations of Plasma Liver-Type Fatty Acid-Binding Protein with Amyloid-β and Tau Levels in Patients with Alzheimer's Disease.

机构信息

Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China.

Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China.

出版信息

J Alzheimers Dis. 2022;88(1):375-383. doi: 10.3233/JAD-220126.

DOI:10.3233/JAD-220126
PMID:35599489
Abstract

BACKGROUND

The dysregulation of lipid metabolism plays an important role in the pathogenesis of Alzheimer's disease (AD). Liver-type fatty acid-binding protein (L-FABP, also known as FABP1) is critical for fatty acid transport and may be involved in AD.

OBJECTIVE

To investigate whether the FABP1 level is altered in patients with AD, and its associations with levels of amyloid-β (Aβ) and tau in the plasma and cerebrospinal fluid (CSF).

METHODS

A cross-sectional study was conducted in a Chinese cohort consisting of 39 cognitively normal controls and 47 patients with AD. The levels of FABP1 in plasma, and Aβ and tau in CSF, were measured by enzyme-linked immunosorbent assay (ELISA). A single-molecule array (SIMOA) was used to detect plasma Aβ levels.

RESULTS

The level of plasma FABP1 was significantly elevated in the AD group (p = 0.0109). Further analysis showed a positive correlation of FABP1 with CSF total tau (t-tau) and phosphorylated tau (p-tau) levels. Besides, plasma FABP1/Aβ42 (AUC = 0.6794, p = 0.0071) and FABP1/t-tau (AUC = 0.7168, p = 0.0011) showed fair diagnostic efficacy for AD. When combined with other common AD biomarkers including plasma Aβ42, Aβ40, and t-tau, both FABP1/Aβ42 and FABP1/t-tau showed better diagnostic efficacy than using these biomarkers alone. Among all AUC analyses, the combination of plasma FABP1/t-tau and Aβ42 had the highest diagnostic value (AUC = 0.8075, p < 0.0001).

CONCLUSION

These findings indicate that FABP1 may play a role in AD pathogenesis and be worthy of further investigation in the future.

摘要

背景

脂代谢失调在阿尔茨海默病(AD)的发病机制中起着重要作用。肝型脂肪酸结合蛋白(L-FABP,也称为 FABP1)对脂肪酸的运输至关重要,并且可能与 AD 有关。

目的

研究 FABP1 水平是否在 AD 患者中发生改变,及其与血浆和脑脊液(CSF)中淀粉样蛋白-β(Aβ)和 tau 的水平的关系。

方法

在中国队列中进行了一项横断面研究,该队列包括 39 名认知正常对照者和 47 名 AD 患者。通过酶联免疫吸附试验(ELISA)测量血浆中 FABP1 以及 CSF 中 Aβ和 tau 的水平。使用单分子阵列(SIMOA)检测血浆 Aβ 水平。

结果

AD 组的血浆 FABP1 水平显著升高(p=0.0109)。进一步分析显示,FABP1 与 CSF 总 tau(t-tau)和磷酸化 tau(p-tau)水平呈正相关。此外,血浆 FABP1/Aβ42(AUC=0.6794,p=0.0071)和 FABP1/t-tau(AUC=0.7168,p=0.0011)对 AD 具有良好的诊断效能。当与其他常见的 AD 生物标志物(包括血浆 Aβ42、Aβ40 和 t-tau)联合使用时,FABP1/Aβ42 和 FABP1/t-tau 均显示出比单独使用这些生物标志物更好的诊断效能。在所有 AUC 分析中,血浆 FABP1/t-tau 和 Aβ42 的组合具有最高的诊断价值(AUC=0.8075,p<0.0001)。

结论

这些发现表明 FABP1 可能在 AD 的发病机制中起作用,值得进一步研究。

相似文献

1
The Correlations of Plasma Liver-Type Fatty Acid-Binding Protein with Amyloid-β and Tau Levels in Patients with Alzheimer's Disease.阿尔茨海默病患者血浆肝型脂肪酸结合蛋白与淀粉样β和tau 水平的相关性。
J Alzheimers Dis. 2022;88(1):375-383. doi: 10.3233/JAD-220126.
2
Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid.磷酸化tau蛋白与Aβ42的比值作为一种连续性状,用于在脑脊液多重免疫分析检测板中发现早期阿尔茨海默病的生物标志物。
Biol Psychiatry. 2014 May 1;75(9):723-31. doi: 10.1016/j.biopsych.2013.11.032. Epub 2014 Jan 19.
3
Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.与临床前阿尔茨海默病核心 CSF 生物标志物相关的纵向结构脑变化:两项独立数据集研究。
Neuroimage Clin. 2018 Apr 16;19:190-201. doi: 10.1016/j.nicl.2018.04.016. eCollection 2018.
4
Assessment of the Correlation and Diagnostic Accuracy between Cerebrospinal Fluid and Plasma Alzheimer's Disease Biomarkers: A Comparison of the Lumipulse and Simoa Platforms.评估脑脊液和血浆阿尔茨海默病生物标志物之间的相关性和诊断准确性:Lumipulse 和 Simoa 平台的比较。
Int J Mol Sci. 2024 Apr 23;25(9):4594. doi: 10.3390/ijms25094594.
5
Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.中国痴呆人群中脑脊液核心阿尔茨海默病生物标志物与β-淀粉样蛋白 PET 的相关性。
ACS Chem Neurosci. 2022 May 18;13(10):1558-1565. doi: 10.1021/acschemneuro.2c00120. Epub 2022 Apr 27.
6
CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.脑脊液淀粉样蛋白 β38 作为路易体痴呆的新型诊断标志物。
J Neurol Neurosurg Psychiatry. 2011 Feb;82(2):160-4. doi: 10.1136/jnnp.2009.199398. Epub 2010 Nov 3.
7
Sexually Dimorphic Association of Circulating Plasminogen Activator Inhibitor-1 Levels and Body Mass Index with Cerebrospinal Fluid Biomarkers of Alzheimer's Pathology in Preclinical Alzheimer's Disease.性二态性与循环纤溶酶原激活物抑制剂-1 水平和体重指数与临床前阿尔茨海默病患者脑脊液阿尔茨海默病病理生物标志物的关联。
J Alzheimers Dis. 2023;91(3):1073-1083. doi: 10.3233/JAD-220686.
8
Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.在常规实践中,将β淀粉样蛋白42(Aβ₄₂)/β淀粉样蛋白40(Aβ₄₀)比值与脑脊液生物标志物磷酸化tau蛋白(P-tau)和Aβ₄₂一起使用,可提高阿尔茨海默病病理生理过程的证据水平。
J Alzheimers Dis. 2014;41(2):377-86. doi: 10.3233/JAD-131838.
9
Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.阿尔茨海默病进展中淀粉样蛋白和 tau 生物标志物的相互预测关系:一个经验模型。
J Neurosci. 2019 Sep 11;39(37):7428-7437. doi: 10.1523/JNEUROSCI.1056-19.2019. Epub 2019 Jul 26.
10
Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.在OPTIMA队列中,脑脊液生物标志物可将经尸检确诊的阿尔茨海默病与其他痴呆症及健康对照区分开来。
J Alzheimers Dis. 2015;44(2):525-39. doi: 10.3233/JAD-141725.

引用本文的文献

1
From Amyloid to Synaptic Dysfunction: Biomarker-Driven Insights into Alzheimer's Disease.从淀粉样蛋白到突触功能障碍:基于生物标志物的阿尔茨海默病见解
Curr Issues Mol Biol. 2025 Jul 22;47(8):580. doi: 10.3390/cimb47080580.
2
Bridging systemic metabolic dysfunction and Alzheimer's disease: the liver interface.连接全身代谢功能障碍与阿尔茨海默病:肝脏的界面
Mol Neurodegener. 2025 May 28;20(1):61. doi: 10.1186/s13024-025-00849-6.
3
Neuronal fatty acid-binding protein enhances autophagy and suppresses amyloid-β pathology in a Drosophila model of Alzheimer's disease.
神经元脂肪酸结合蛋白增强自噬并抑制阿尔茨海默病果蝇模型中的淀粉样β病理学。
PLoS Genet. 2024 Nov 19;20(11):e1011475. doi: 10.1371/journal.pgen.1011475. eCollection 2024 Nov.
4
Associations of Serum Liver Function with Cerebral Blood Flow in Patients with Alzheimer's Disease.阿尔茨海默病患者血清肝功能与脑血流量的相关性
J Alzheimers Dis Rep. 2024 Mar 15;8(1):437-445. doi: 10.3233/ADR-230102. eCollection 2024.
5
Brain insulin resistance and Alzheimer's disease: a systematic review.脑胰岛素抵抗与阿尔茨海默病:一项系统综述。
Dement Neuropsychol. 2024 Feb 9;18:e20230032. doi: 10.1590/1980-5764-DN-2023-0032. eCollection 2024.